1-propyl sec-butyl disulfide | 59849-54-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 有机二硫化物
• 英文名称: 1-propyl sec-butyl disulfide
• 英文别名: n-propyl sec-butyl disulfide；propyl sec-butyl disulfide；sec-butyl propyl disulfide；Disulfide, 1-methylpropyl propyl；2-(propyldisulfanyl)butane
• CAS: 59849-54-6
• 化学式: C₇H₁₆S₂
• 分子量: 164.336
• InChiKey: KHTNPVYWCGRQEA-UHFFFAOYSA-N

物化性质

• 沸点：
  205.9±9.0 °C(Predicted)
• 密度：
  0.953±0.06 g/cm3(Predicted)
• 保留指数：
  1172

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  50.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  二仲丁基二硫醚 、 二丙基二硫 以 环己烷 为溶剂， 生成 1-propyl sec-butyl disulfide
  参考文献：
  名称：

  Gupta, D., Acta Chimica Academiae Scientiarum Hungaricae, 1981, vol. 108, # 1, p. 31 - 36

  摘要：

  DOI：

文献信息

• Dosages and methods for delivering lipid formulated nucleic acid molecules
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US10246708B2

  公开（公告）日：2019-04-02

  Methods, kits and devices for dosing a subject to reduce a hypersensitivity response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed.

  本发明公开了用于给受试者用药以降低其对脂质配制的核酸（如 RNA）分子的超敏反应的方法、试剂盒和装置。
• Gupta, Dinesh; Knight, Arthur R., Canadian Journal of Chemistry, 1980, vol. 58, p. 1350 - 1354
  作者：Gupta, Dinesh、Knight, Arthur R.

  DOI：——

  日期：——
• [EN] ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF<br/>[FR] ANTICORPS NEUTRALISANTS MODIFIÉS CONTRE LE VIRUS DE L'HÉPATITE B ET UTILISATIONS ASSOCIÉES
  申请人：VIR BIOTECHNOLOGY INC

  公开号：WO2021262840A1

  公开（公告）日：2021-12-30

  The present disclosure relates, in part, to antibodies, and antigen-binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and,optionally, can neutralize infection hepatitis B virus (HBV), and further optionally, of hepatitis delta virus (HDV). Presently disclosed antibodies and antigen-binding fragments have advantageous production characteristics, such as reduced formation of aggregates and/or improved production titer in transformed host cells, as compared to a reference antibody or antigen-binding fragment. The present disclosure also relates to to fusion proteins that comprise an antigen-binding fragment, and to nucleic acids that encode and cells that produce such antibodies, antigen-binding fragments, and fusion proteins. In addition, the present disclosure relates to the use of the antibodies, antigen-binding fragments, fusion proteins, and related polynucleotides, vectors, host cells, and compositions of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D. Also provided are combination therapies comprising (i) an antibody or antigen-binding fragment and (ii) an agent that is an inhibitor of HBV gene expression and/or that reduces HBV antigenic load.
• Gupta, D., Acta Chimica Academiae Scientiarum Hungaricae, 1981, vol. 108, # 1, p. 31 - 36
  作者：Gupta, D.

  DOI：——

  日期：——

表征谱图